| dc.contributor.author | Egieyeh, Samuel | |
| dc.contributor.author | Dube, Admire | |
| dc.date.accessioned | 2022-01-25T13:15:49Z | |
| dc.date.available | 2022-01-25T13:15:49Z | |
| dc.date.issued | 2021 | |
| dc.identifier.citation | Dube, A.; Egieyeh, S.; Balogun, M. A Perspective on Nanotechnology and COVID-19 Vaccine Research and Production in South Africa. Viruses 2021, 13, 2095. https://doi.org/10.3390/v13102095 | en_US |
| dc.identifier.uri | https://doi.org/10.3390/v13102095 | |
| dc.identifier.uri | http://hdl.handle.net/10566/7127 | |
| dc.description.abstract | Advances in nanotechnology have enabled the development of a new generation of
vaccines, which are playing a critical role in the global control of the COVID-19 pandemic and
the return to normalcy. Vaccine development has been conducted, by and large, by countries in
the global north. South Africa, as a major emerging economy, has made extensive investments in
nanotechnology and bioinformatics and has the expertise and resources in vaccine development
and manufacturing. This has been built at a national level through decades of investment. In
this perspective article, we provide a synopsis of the investments made in nanotechnology and
highlight how these could support innovation, research, and development for vaccines for this
disease. We also discuss the application of bioinformatics tools to support rapid and cost-effective
vaccine development and make recommendations for future research and development in this area
to support future health challenges. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | MDPI | en_US |
| dc.subject | COVID-19 and nanotechnology | en_US |
| dc.subject | Nanomedicine in South Africa | en_US |
| dc.subject | Bioinformatics and vaccine development | en_US |
| dc.subject | vaccine development in South Africa | en_US |
| dc.title | A perspective on nanotechnology and covid-19 vaccine research and production in south africa | en_US |
| dc.type | Article | en_US |
